| Upfront Value | ₹10.00 CrDeal Consideration |
|---|---|
| Market Cap | ₹4,049.04 CrPharmaceuticals |
| TTM Net Profit | ₹97.77 CrGrowth: -7.65% |
| RSI | 61.13Neutral Zone |
| Deal value | ₹10 Cr |
| Share of market cap | 0.2% |
| Share of annual revenue | 2.7% |
Key highlights
- Exclusive rights to promote and distribute Accentrix (ranibizumab) and Pagenax (brolucizumab)
- Upfront consideration of ₹10 crore payable to Novartis Healthcare Private Limited
- Strategic entry into the Indian ophthalmology therapy market to expand commercial portfolio
- Agreement executed and effective as of September 8, 2026
- Targeted treatments for chronic retinal conditions like macular degeneration and edema
What Is the Partnership?
The agreement, executed on September 8, 2026, grants Novartis India Limited (NIL) exclusive rights to promote and distribute the retina portfolio of Novartis Healthcare Private Limited (NHPL) within the Indian territory. The deal focuses on two primary ophthalmology products: Accentrix (ranibizumab) and Pagenax (brolucizumab). In exchange for these exclusive commercial rights, Novartis India will pay an upfront consideration of ₹10 crore to NHPL.
This arrangement allows the listed entity to leverage established therapeutic brands to drive top-line growth without the immediate overhead of internal product development for the ophthalmology segment.
Partner Profile
- Novartis Healthcare Private Limited (NHPL) operates as a private entity within the broader Novartis group in India
- The counterparty manages a diverse portfolio of innovative medicines and specializes in complex therapy areas including oncology
- NHPL holds the marketing authorizations for advanced biologics such as ranibizumab in the domestic market
- This partnership reflects a strategic realignment to optimize the distribution and reach of specialized retina treatments
What It Unlocks
The partnership serves as a gateway for Novartis India to establish a foothold in the high-growth ophthalmology market. By acquiring the rights to Accentrix and Pagenax, the company gains immediate access to therapies used for treating retinal disorders such as wet age-related macular degeneration and diabetic macular edema. These chronic conditions require long-term management, potentially providing a steady revenue stream for the distributor.
This entry into a new therapy area is expected to diversify the revenue base of the listed entity, which has historically focused on segments like pain management and anti-infectives.
Financial Context
- Novartis India reported a TTM revenue of ₹370.59 crore, with the ₹10 crore upfront payment representing a tactical investment
- The company maintains a healthy operating profit margin of 33.63% as of the June 2026 quarter
- Promoter holding remains stable at 70.68%, indicating consistent parent support for domestic strategic initiatives
- The stock has demonstrated significant momentum with a one-year price return of 75.88% as of September 2026
| Share price | ₹1639.9 |
|---|---|
| Market capitalisation | ₹4,049.04 Cr |
| Revenue (annual) | ₹354.33 Cr |
| Net profit (annual) | ₹93.18 Cr |
| Revenue (latest quarter) | ₹103.81 Cr+14.64% vs previous quarter |
| Net profit (latest quarter) | ₹32.21 Cr+27.56% vs previous quarter |
| P/E (TTM) | 41.41×Sector 48.79× |
| Promoter holding | 70.68%0.00% QoQ |
| FII holding | 0.15%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Novartis India Limited announcing an Exclusive Promotion and Distribution Agreement for its retina portfolio. Market figures from a third-party data provider.
